{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:29:17Z","timestamp":1791008957653,"version":"4.1.0"},"reference-count":74,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Anemia is a common and progressive clinical manifestation of myelofibrosis that may occur as part of the disease pathogenesis as well as due to the myelosuppressive effects of some treatments, with a substantial impact on quality of life, prognosis, and healthcare resource utilization. Despite these burdens, anemia management has traditionally been a secondary priority to spleen and symptom control, due in part to the limitations of available therapeutic approaches. With the initial regulatory approvals of momelotinib, a Janus kinase 1 (JAK1), JAK2, and activin A receptor type 1 inhibitor that provides anemia-related benefits in addition to addressing splenomegaly and symptoms, re-evaluation of anemia as an early and prominent treatment consideration is warranted. Methods: In this review, we discuss the journey of patients with myelofibrosis and anemia across various severities and clinical scenarios. Results: Summarized are traditional approaches to anemia management and the clinical trial efficacy and safety data that support momelotinib as an option in each setting from mild to severe anemia, including in the context of co-occurring thrombocytopenia. Conclusions: With the availability of momelotinib and other emerging therapies directed at anemia control, early treatment of anemia to avoid progression and support improvement in eligible patients with myelofibrosis should be a primary consideration.<\/jats:p>","DOI":"10.3390\/cancers16234064","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T10:07:10Z","timestamp":1733306830000},"page":"4064","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-2239","authenticated-orcid":false,"given":"Haifa Kathrin","family":"Al-Ali","sequence":"first","affiliation":[{"name":"Krukenberg Cancer Center Halle, University Hospital Halle, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-7415","authenticated-orcid":false,"given":"Andrew T.","family":"Kuykendall","sequence":"additional","affiliation":[{"name":"Moffit Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7635-7846","authenticated-orcid":false,"given":"Catherine E.","family":"Ellis","sequence":"additional","affiliation":[{"name":"GSK plc, Collegeville, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9001-6657","authenticated-orcid":false,"given":"Janardhan","family":"Sampath","sequence":"additional","affiliation":[{"name":"GSK plc, Collegeville, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-7972","authenticated-orcid":false,"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: Current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"Hemasphere"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: The Mayo Clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2013.72","article-title":"Myelofibrosis, JAK2 inhibitors and erythropoiesis","volume":"27","author":"Vainchenker","year":"2013","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.exphem.2014.10.013","article-title":"C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients","volume":"43","author":"Wang","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ajh.23406","article-title":"Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis","volume":"88","author":"Pardanani","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11899-018-0447-9","article-title":"Management of myelofibrosis-related cytopenias","volume":"13","author":"Bose","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.34722","article-title":"Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome","volume":"129","author":"Palandri","year":"2023","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mesa, R.A., Palandri, F., Verstovsek, S., Masarova, L., Harrison, C., Mazerolle, F., Gorsh, B., M\u2019Hari, M., Wang, Z., and Ellis, C.E. (2023, January 2\u20138). Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2). Poster 7066. Proceedings of the 2023 ASCO Annual Meeting, Chicago, IL, USA.","DOI":"10.1200\/JCO.2023.41.16_suppl.7066"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Palmer, J., Mazerolle, F., Liu, T., M\u2019Hari, M., Regnault, A., Zhang, S., Cardellino, A., Wang, Z., Strouse, B., and Sahni, J. (June, January 31). Association between hemoglobin improvement and patient-reported outcomes in patients with myelofibrosis and anemia: Post hoc pooled analysis of momelotinib phase 3 trials. Poster 6574. Proceedings of the 2024 ASCO Annual Meeting, Chicago, IL, USA.","DOI":"10.1200\/JCO.2024.42.16_suppl.6574"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","article-title":"Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: Analysis based on 1109 consecutive patients","volume":"32","author":"Nicolosi","year":"2018","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"key":"ref_16","unstructured":"Al-Ali, H.K., Guglielmelli, P., Hamer-Maansson, J.E., Braunstein, E., and Gupta, V. (2024, January 13\u201316). The impact of new or worsening anemia on clinical outcomes in 2233 patients with myelofibrosis treated with ruxolitinib: Results from the expanded-access JUMP study. Poster P1044. Proceedings of the EHA 2024 Hybrid Congress, Madrid, Spain."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/cncr.35156","article-title":"Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy","volume":"130","author":"Palandri","year":"2023","journal-title":"Cancer"},{"key":"ref_18","first-page":"1395","article-title":"Evaluating estimated health care resource utilization and costs in patients with myelofibrosis based on transfusion status and anemia severity: A retrospective analysis of the Medicare Fee-For-Service claims data","volume":"30","author":"Gerds","year":"2024","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00277-023-05126-4","article-title":"How I manage anemia related to myelofibrosis and its treatment regimens","volume":"102","author":"Verstovsek","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_20","unstructured":"Omjjara [Momelotinib] (2024, November 25). Summary of Product Characteristics. GSK. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omjjara-epar-product-information_en.pdf."},{"key":"ref_21","unstructured":"GSK (2024, November 25). Press Release. Available online: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-s-omjjara-momelotinib-approved-in-japan-for-treatment-of-myelofibrosis\/."},{"key":"ref_22","unstructured":"(2024, November 25). GOV.UK, Available online: https:\/\/www.gov.uk\/government\/news\/omjjara-licensed-for-anaemic-myelofibrosis-patients-to-treat-the-symptoms-of-their-disease."},{"key":"ref_23","unstructured":"Ojjaara [Momelotinib] (2024, November 25). Prescribing Information. GSK. Available online: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Ojjaara\/pdf\/OJJAARA-PI-PIL.PDF."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: An emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv."},{"key":"ref_27","unstructured":"Vonjo (Pacritinib) (2024, November 25). Prescribing Information. CTI BioPharma Corp. Available online: https:\/\/www.ctibiopharma.com\/wp-content\/uploads\/2022\/02\/VONJO_USPI.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: A phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10612","DOI":"10.1002\/cam4.5799","article-title":"Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies","volume":"12","author":"Mesa","year":"2023","journal-title":"Cancer Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/10428194.2024.2328800","article-title":"Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial","volume":"65","author":"Gupta","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e963","DOI":"10.1097\/HS9.0000000000000963","article-title":"Momelotinib in myelofibrosis patients with thrombocytopenia: Post hoc analysis from three randomized phase 3 trials","volume":"7","author":"Kiladjian","year":"2023","journal-title":"Hemasphere"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","article-title":"Momelotinib long-term safety and survival in myelofibrosis: Integrated analysis of phase 3 randomized-controlled trials","volume":"7","author":"Verstovsek","year":"2023","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Harrison, C.N., Mesa, R., Talpaz, M., Gupta, V., Gerds, A.T., Perkins, A., Goh, Y.T., Fox, M.L., McLornan, D., and Palmer, J. (2024). Longitudinal assessment of transfusion intensity in patients with JAK inhibitor-naive or -experienced myelofibrosis treated with momelotinib. Clin. Lymphoma Myeloma Leuk., ahead of print.","DOI":"10.1016\/j.clml.2024.10.001"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3324\/haematol.2023.283106","article-title":"Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib","volume":"109","author":"Mesa","year":"2024","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1007\/s12325-024-02928-4","article-title":"Momelotinib versus continued ruxolitinib or best available therapy in JAK inhibitor-experienced patients with myelofibrosis and anemia: Subgroup analysis of SIMPLIFY-2","volume":"41","author":"Harrison","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_39","unstructured":"World Health Organization (2024, November 25). Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/85839\/WHO_NMH_NHD_MNM_11.1_eng.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e2119123","DOI":"10.1001\/jamanetworkopen.2021.19123","article-title":"Evaluation of hemoglobin cutoff levels to define anemia among healthy individuals","volume":"4","author":"Addo","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_41","unstructured":"(2024, November 25). Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0; Published 27 November 2017, Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","article-title":"Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Vannucchi","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: Updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kroger","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ajh.27274","article-title":"2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management","volume":"99","author":"Ali","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Bacigalupo, A., Innocenti, I., Rossi, E., Sora, F., Galli, E., Autore, F., Metafuni, E., Chiusolo, P., Giammarco, S., and Laurenti, L. (2021). Allogeneic hemopoietic stem cell transplantation for myelofibrosis: 2021. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.637512"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_49","unstructured":"Inrebic (Fedratinib) (2024, November 25). Prescribing Information. Bristol Myers Squibb. Available online: https:\/\/packageinserts.bms.com\/pi\/pi_inrebic.pdf."},{"key":"ref_50","unstructured":"Jakafi (Ruxolitinib) (2024, November 25). Prescribing Information. Incyte. Available online: https:\/\/www.jakafi.com\/pdf\/prescribing-information.pdf."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood.2024025802","article-title":"Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis","volume":"144","author":"Tefferi","year":"2024","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.15450","article-title":"The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib","volume":"182","author":"Crisa","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01266.x","article-title":"Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level","volume":"83","author":"Huang","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","article-title":"Danazol therapy for the anemia of myelofibrosis: Assessment of efficacy with current criteria of response and long-term results","volume":"94","author":"Cervantes","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2141.2005.05524.x","article-title":"Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: Long-term results in 30 patients","volume":"129","author":"Cervantes","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2010-12-325589","article-title":"Comparison of thalidomide and lenalidomide as therapy for myelofibrosis","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1182\/bloodadvances.2024012939","article-title":"Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis","volume":"8","author":"Gerds","year":"2024","journal-title":"Blood Adv."},{"key":"ref_60","unstructured":"(2024, November 25). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04717414."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-020-00392-1","article-title":"Ruxolitinib discontinuation syndrome: Incidence, risk factors, and management in 251 patients with myelofibrosis","volume":"11","author":"Palandri","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS","volume":"96","author":"Elena","year":"2011","journal-title":"Haematologica"},{"key":"ref_64","unstructured":"Verstovsek, S., Oh, S.T., Kiladjian, J.J., Platzbecker, U., Passamonti, F., Gerds, A.T., Vannucchi, A.M., McLornan, D.P., Gupta, V., and Grosicki, S. (2022, January 10\u201313). Transfusion independence response as a potential surrogate for overall survival in JAKi-experienced patients with myelofibrosis from MOMENTUM. Poster 3028. Proceedings of the 65th Annual ASH Meeting & Exposition, New Orleans, LA, USA."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/s41375-022-01637-7","article-title":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis","volume":"36","author":"Mesa","year":"2022","journal-title":"Leukemia"},{"key":"ref_66","unstructured":"Gerds, A.T., Harrison, C., Thompson, S., Snopek, F., and Pemmaraju, N. (2022, January 10\u201313). The burden of illness and the incremental burden of transfusion dependence in myelofibrosis in the United States. Poster 1729. Proceedings of the 65th Annual ASH Meeting & Exposition, New Orleans, LA, USA."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.blre.2016.04.003","article-title":"Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes","volume":"30","author":"Carreau","year":"2016","journal-title":"Blood Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1423-0410.2009.01207.x","article-title":"Iron overload and toxicity: The hidden risk of multiple blood transfusions","volume":"97","author":"Shander","year":"2009","journal-title":"Vox Sang."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-020-02920-y","article-title":"High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity","volume":"112","author":"Caocci","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Chifotides, H.T., Verstovsek, S., and Bose, P. (2023). Association of myelofibrosis phenotypes with clinical manifestations, molecular profiles, and treatments. Cancers, 15.","DOI":"10.3390\/cancers15133331"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ejh.13005","article-title":"Significance of thrombocytopenia in patients with primary and postessential thrombocythemia\/polycythemia vera myelofibrosis","volume":"100","author":"Masarova","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Mascarenhas, J., Gerds, A.T., Kiladjian, J.J., Dohner, K., Buckley, S., Smith, J.A., Craig, A.R., Singh, S.B., Verstovsek, S., and Harrison, C. (2022, January 10\u201313). PACIFICA: A randomized, controlled phase 3 study of pacritinib versus physician\u2019s choice in patients with primary or secondary myelofibrosis and severe thrombocytopenia. Poster 4316. Proceedings of the 65th Annual ASH Meeting & Exposition, New Orleans, LA, USA.","DOI":"10.1182\/blood-2022-163456"},{"key":"ref_73","unstructured":"Segura, A., Garcia Delgado, R., Perez Lamas, L., Senin Magan, M.A., Fox, M.L., Trejos Carvajal, D.M., Ossorio Prendes, O., de las Hera, N., Angona Figueras, A., and Carreno Gomez-Tarragona, G. (2024, January 13\u201316). Real-world outcomes of momelotinib as an alternative therapy to other JAK inhibitors in myelofibrosis patients with anemia. Poster P1067. Proceedings of the EHA 2024 Hybrid Congress, Madrid, Spain."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1007\/s00277-024-05908-4","article-title":"MoReLife\u2014Real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients","volume":"103","author":"Jilg","year":"2024","journal-title":"Ann. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/23\/4064\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:46:53Z","timestamp":1760114813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/23\/4064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":74,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16234064"],"URL":"https:\/\/doi.org\/10.3390\/cancers16234064","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]}}}